183 related articles for article (PubMed ID: 36034784)
1. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis
Wang L; Otkur W; Wang A; Wang W; Lyu Y; Fang L; Shan X; Song M; Feng Y; Zhao Y; Piao HL; Qi H; Liu JW
Front Pharmacol; 2022; 13():906043. PubMed ID: 36034784
[TBL] [Abstract][Full Text] [Related]
2. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy
Li H; Wang Y; Su R; Jia Y; Lai X; Su H; Fan Y; Wang Y; Xing W; Qin J
Front Oncol; 2022; 12():794216. PubMed ID: 35141161
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
5. Silencing
Liu C; He S; Zhang J; Li S; Chen J; Han C
Onco Targets Ther; 2020; 13():4905-4915. PubMed ID: 32581551
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
8. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
9. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
11. Tracking of Glycans Structure and Metallomics Profiles in
Nisiewicz MK; Kowalczyk A; Sobiepanek A; Jagielska A; Wagner B; Nowakowska J; Gniadek M; Grudzinski IP; Kobiela T; Nowicka AM
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406789
[TBL] [Abstract][Full Text] [Related]
12. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
[TBL] [Abstract][Full Text] [Related]
13. RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Data Brief; 2020 Jun; 30():105610. PubMed ID: 32382617
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis.
Tang F; Li S; Liu D; Chen J; Han C
Transl Cancer Res; 2020 Mar; 9(3):1584-1593. PubMed ID: 35117506
[TBL] [Abstract][Full Text] [Related]
15. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
16. The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.
Jiang SL; Wang ZB; Zhu T; Jiang T; Fei JF; Liu C; Luo C; Cheng Y; Liu ZQ
Front Pharmacol; 2021; 12():720619. PubMed ID: 34512348
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expression.
Wang Z; You D; Lu M; He Y; Yan S
Oncol Lett; 2017 Mar; 13(3):1660-1664. PubMed ID: 28454306
[TBL] [Abstract][Full Text] [Related]
18. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
